GoldhirschA, WoodWC, GelberRD, CoatesAS, ThurlimannB, SennHJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol.2007; 18: 1133–1144.
2.
GoldhirschA, IngleJN, GelberRD, CoatesAS, ThurlimannB, SennHJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol.2009; 20: 1319–1329.
3.
EifelP, AxelsonJA, CostaJ. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst.2001; 93: 979–989.
4.
GaleaMH, BlameyRW, ElstonCE, EllisIO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat.1992; 22: 207–219.
5.
SorlieT, PerouCM, TibshiraniR. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A.2001; 98: 10869–10874.
6.
SorlieT, TibshiraniR, ParkerJ. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A.2003; 100: 8418–8423.
7.
BrentonJD, CareyLA, AhmedAA, CaldasC. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?J Clin Oncol.2005; 23: 7350–7360.
8.
RakhaEA, El-SayedME, Reis-FilhoJS, EllisIO. Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology.2008; 52: 67–81.
9.
ParkerJS, MullinsM, CheangMC. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol.2009; 27: 1160–1167.
10.
SotiriouC, PusztaiL. Gene-expression signatures in breast cancer. N Engl J Med.2009; 360: 790–800.
11.
GeyerFC, Reis-FilhoJS. Microarray-based gene expression profiling as clinical tool for breast cancer management: are we there yet?Int J Surg Pathol.2009; 17: 285–302.
12.
RakhaE, Reis-FilhoJS. Basal-like breast carcinoma: from expression profiling to routine practice. Arch Pathol Lab Med.2009; 133: 860–868.
13.
LivasyCA, KaracaG, NandaR. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol.2006; 19: 264–271.
14.
FulfordLG, EastonDF, Reis-FilhoJS. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology.2006; 49: 22–34.
15.
FadareO, TavassoliFA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol.2007; 14: 358–373.
16.
DiazLK, CrynsVL, SymmansWF, SneigeN. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol.2007; 14: 419–430.
17.
LaaksoM, LomanN, BorgA, IsolaJ. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol.2005; 18: 1321–1328.
18.
FulfordLG, Reis-FilhoJS, RyderK. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res.2007; 9: R4.
19.
SchneiderBP, WinerEP, FoulkesWD. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res.2008; 14: 8010–8018.
20.
MoinfarF. Is “basal-like” carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. Pathobiology.2008; 75: 119–131.
21.
TurnerNC, Reis-FilhoJS, RussellAM. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene.2007; 26: 2126–2132.
22.
RakhaEA, Reis-FilhoJS, EllisIO. Basal-like breast cancer: a critical review. J Clin Oncol.2008; 26: 2568–2581.
23.
TurnerNC, Reis-FilhoJS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene.2006; 25: 5846–5853.
24.
MillikanRC, NewmanB, TseCK. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat.2008; 109: 123–139.
25.
BanerjeeS, Reis-FilhoJS, AshleyS. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol.2006; 59: 729–735.
26.
Da SilvaL, ClarkeC, LakhaniSR. Demystifying basal-like breast carcinomas. J Clin Pathol.2007; 60: 1328–1332.
27.
RakhaEA, El-SayedME, Reis-FilhoJ, EllisIO. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat.2009; 113: 411–422.
28.
RakhaEA, ElsheikhSE, AleskandaranyMA. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res.2009; 15: 2302–2310.
29.
CheangMC, ChiaSK, VoducD. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst.2009; 101: 736–750.
30.
NielsenTO, HsuFD, JensenK. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res.2004; 10: 5367–5374.
31.
CheangMC, VoducD, BajdikC. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res.2008; 14: 1368–1376.
32.
WeigeltB, HorlingsHM, KreikeB. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol.2008; 216: 141–150.
33.
IvshinaAV, GeorgeJ, SenkoO. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res.2006; 66: 10292–10301.
34.
SotiriouC, WirapatiP, LoiS. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst.2006; 98: 262–272.
35.
IgnatiadisM, SotiriouC. Understanding the molecular basis of histologic grade. Pathobiology.2008; 75: 104–111.
36.
RossJS, HatzisC, SymmansWF, PusztaiL, HortobagyiGN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist.2008; 13: 477–493.
37.
FongPC, BossDS, YapTA. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med.2009; 361: 123–134.
38.
RakhaEA, Reis-FilhoJS, EllisIO. Impact of basal-like breast carcinoma determination for a more specific therapy. Patho-biology.2008; 75: 95–103.
39.
FoulkesWD, StefanssonIM, ChappuisPO. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst.2003; 95: 1482–1485.
40.
LakhaniSR, Reis-FilhoJS, FulfordL. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res.2005; 11: 5175–5180.
41.
EerolaH, HeinonenM, HeikkilaP. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res.2008; 10:R17.
42.
CollinsLC, MartyniakAJ, KandelMJ. Basal cyto-keratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol.2009; 33: 1093–1097.
